| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G/A | 2020-02-14 | SANDS CAPITAL MANAGEMENT, LLC | Loxo Oncology, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2020-01-08 | WELLINGTON MANAGEMENT GROUP LLP | Loxo Oncology, Inc. | 0 | 0.0% | EDGAR |
| SC 13D/A | 2019-02-15 | AISLING CAPITAL III LP | Loxo Oncology, Inc. | 0 | 0.0% | EDGAR |
| SC 13D/A | 2019-02-15 | LILLY ELI & CO | Loxo Oncology, Inc. | - | - | EDGAR |
| SC 13G/A | 2019-02-14 | PRICE T ROWE ASSOCIATES INC /MD/ | Loxo Oncology, Inc. | 2,116,328 | 6.9% | EDGAR |
| SC 13G/A | 2019-02-13 | ADAGE CAPITAL PARTNERS GP, L.L.C. | Loxo Oncology, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2019-02-12 | WELLINGTON MANAGEMENT GROUP LLP | Loxo Oncology, Inc. | 1,793,587 | 5.9% | EDGAR |
| SC 13G/A | 2019-02-11 | FMR LLC | Loxo Oncology, Inc. | 414,902 | 1.3% | EDGAR |
| SC 13G/A | 2019-02-11 | VANGUARD GROUP INC | Loxo Oncology, Inc. | 2,789,978 | 9.1% | EDGAR |
| SC 13G/A | 2019-02-08 | FMR LLC | Loxo Oncology, Inc. | 1,997,330 | 6.5% | EDGAR |
| SC 13G/A | 2019-02-06 | BlackRock Inc. | Loxo Oncology, Inc. | 2,280,968 | 7.5% | EDGAR |
| SC 13D/A | 2019-01-15 | AISLING CAPITAL III LP | Loxo Oncology, Inc. | 2,038,920 | 6.7% | EDGAR |
| SC 13D | 2019-01-15 | LILLY ELI & CO | Loxo Oncology, Inc. | 2,038,920 | 6.6% | EDGAR |
| SC 13G/A | 2019-01-10 | SANDS CAPITAL MANAGEMENT, LLC | Loxo Oncology, Inc. | 1,722,467 | 5.6% | EDGAR |
| SC 13D/A | 2018-07-12 | AISLING CAPITAL III LP | Loxo Oncology, Inc. | 2,038,920 | 6.8% | EDGAR |
| SC 13G/A | 2018-07-10 | FMR LLC | Loxo Oncology, Inc. | 2,300,702 | 7.6% | EDGAR |
| SC 13D/A | 2018-06-06 | ACCESS INDUSTRIES MANAGEMENT, LLC | Loxo Oncology, Inc. | 857,982 | - | EDGAR |
| SC 13G | 2018-02-14 | PRICE T ROWE ASSOCIATES INC /MD/ | Loxo Oncology, Inc. | 1,595,137 | 5.3% | EDGAR |
| SC 13G | 2018-02-14 | SANDS CAPITAL MANAGEMENT, LLC | Loxo Oncology, Inc. | 2,272,109 | 7.6% | EDGAR |
| SC 13G/A | 2018-02-13 | FMR LLC | Loxo Oncology, Inc. | 4,490,625 | 15.0% | EDGAR |